Premium
The neoadjuvant therapy of colorectal hepatic metastases and the role of biologic sensitizing and resistance factors
Author(s) -
Wanebo Harold J.,
Berz David
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21691
Subject(s) - medicine , colorectal cancer , oncology , metastasis , chemotherapy , neoadjuvant therapy , systemic therapy , disease , cancer , breast cancer
Liver metastasis represents a common systemic complication of colorectal cancers (CRCs). Partial liver resection has been demonstrated to result in long‐term survival in certain well‐selected patients with otherwise well‐controlled systemic disease. Neoadjuvant therapy has been demonstrated to result in improved resectability and potentially longer survival in patients with liver metastases from CRC. The addition of biologic agents to chemotherapy has been shown to improve response rates and overall survival in patients with metastatic CRC. Here, we are discussing the role of biologic agents in the treatment of patients with liver metastases from CRC. We also discuss the role of biomarkers for response and resistance to such novel therapies. J. Surg. Oncol. 2010;102:891–897. © 2010 Wiley‐Liss, Inc.